BioMarin has requested an extension to the timelines for this re-evaluation to respond to issues concerning their evidence submission to NICE. NICE has accepted this request to ensure that BioMarin has the best opportunity to present more complete data on patients receiving treatment with elosulfase alfa. As such, we will need to cancel the committee meeting on 10 June and re-arrange the committee meeting date. We will update you as soon as these new proposed timelines are available